Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and is responsible as one of the main causes of mortality in both men and women. Despite massive efforts to raise public awareness on early screening and significant advancements in the treatment for CRC, the majority...
Guardado en:
Autores principales: | Hidayati Husainy Hasbullah, Marahaini Musa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b4a1bfebaeec44c18aa6dfaa0dbf5002 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
por: Olga I. Brovkina, et al.
Publicado: (2021) -
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Gongmin Zhu, et al.
Publicado: (2021) -
CRISPR and KRAS: a match yet to be made
por: Guzide Bender, et al.
Publicado: (2021) -
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu X, et al.
Publicado: (2019) -
Mutación del gen p53 en el cáncer de colon y recto
por: Roa S,Juan Carlos, et al.
Publicado: (2000)